Cite
HARVARD Citation
Lewis, P. et al. (n.d.). 71: Early experience with osimertinib as second line treatment for EGFR mutated non-small cell lung cancer (NSCLC) and detecting T790M mutations from plasma circulating tumour DNA (ctDNA). Lung cancer. pp. S34-. [Online].